PCSK9 and coronary atherosclerosis: Along with the undeniable clinical cardiovascular benefit of adding PCSK9 inhibitors to a standard lipid-lowering therapy [79, 80], new imaging approaches have allowed us to characterize the impact of these agents on coronary atherosclerosis [81], highlighting the relationship between achieved LDLc levels and plaque progression with more intensive lipid-lowering regimens [82].